- Founded
- 2001
- Business Model
- B2B
- Website
- alligatorbioscience.se
- Total Funding
- $9.6M
- Last Round
- $9.6M Venture RoundDec 2025
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 1 funding round for this company. The full record is or through the API.
About
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, with a focus on the CD40 receptor pathway. By activating the patient's immune system inside the tumor microenvironment, its candidates aim to overcome immune suppression and drive anti-tumor responses. The lead asset, mitazalimab, is a CD40 agonist in preparation for Phase 3 after the Phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer. The pipeline also includes mono- and bispecific antibody programs designed for localized immune activation. Founded in 2001, the company is listed on Nasdaq Stockholm under the ticker ATORX.
Summary
It has raised $9.6M in total across 1 round, most recently a $9.6M Venture Round in Dec 2025.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Dec 2025
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
China's leading blood products manufacturer
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/alligator-bioscience"><img src="https://indexed.vc/api/badge/company/alligator-bioscience" alt="Alligator Bioscience on Indexed.vc" width="260" height="76" /></a>